World's Best Scientists 2026 revealed!
Christoph C. Zielinski

Christoph C. Zielinski

D-Index & Metrics

Medicine

D-Index
104
Citations
40847
World Ranking
7035
National Ranking
34

Overview

Christoph C. Zielinski is affiliated with the Medical University of Vienna in Austria and has contributed extensively to the field of medicine, particularly focusing on oncology. Their research spans over 143 publications, with a significant emphasis on oncology, represented by 67 publications within this subfield.

The scientist's work covers several specialized subfields, including pulmonary and respiratory medicine, immunology, economics and econometrics, and radiology, nuclear medicine, and imaging. This multidisciplinary approach supports a comprehensive exploration of cancer and associated treatments.

Among the main research topics Christoph C. Zielinski has explored are:

  • Advanced Breast Cancer Therapies
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Monoclonal and Polyclonal Antibodies Research
  • HER2/EGFR in Cancer Research
  • Economic and Financial Impacts of Cancer
  • Colorectal Cancer Treatments and Studies

Their publications are frequently found in well-known oncology-related journals. The most common venues for their work include:

  • Annals of Oncology
  • Cancer Research
  • Clinical Cancer Research
  • European Journal of Cancer
  • Journal of Clinical Oncology

Some of the recent papers authored or co-authored by Christoph C. Zielinski are:

  • Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial, 2023, Nature Medicine
  • Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders, 2021, Cancer Discovery
  • Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL, 2020, Annals of Oncology
  • Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated systematic review and meta-analysis of randomized controlled trials, 2020, Research and Practice in Thrombosis and Haemostasis
  • Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring, 2021, ESMO Open

Collaboration is a key component of their research efforts. Frequent co-authors include:

  • Ursula Wiedermann
  • Erika Garner-Spitzer
  • Michael Kundi
  • Miguel Gil-Gil
  • Montserrat Muñoz

Best Publications

  • Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

    Tudor Ciuleanu;Thomas Brodowicz;Christoph Zielinski;Joo Hang Kim

  • 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours

    M. S. Aapro;J. Bohlius;David Cameron;Lissandra Dal Lago

  • Therapeutic vaccines for cancer: an overview of clinical trials

    Ignacio Melero;Gustav Gaudernack;Winald Gerritsen;Christoph Huber

  • Prediction of venous thromboembolism in cancer patients

    Cihan Ay;Daniela Dunkler;Christine Marosi;Alexandru-Laurentiu Chiriac

  • Cardiac Toxicity of Sunitinib and Sorafenib in Patients With Metastatic Renal Cell Carcinoma

    Manuela Schmidinger;Christoph C. Zielinski;Ursula M. Vogl;Andja Bojic

  • Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

    Gunter von Minckwitz;Andreas du Bois;Marcus Schmidt;Nicolai Maass

  • Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer

    Vivek Subbiah;Robert J. Kreitman;Zev A. Wainberg;Jae Yong Cho

  • EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours

    Matti Aapro;David A Cameron;Ruth Pettengell;Julia Bohlius

  • A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)

    Nathan I. Cherny;Richard Sullivan;U. Dafni;J. M. Kerst

  • Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

    Anna Sophie Berghoff;Barbara Kiesel;Georg Widhalm;Orsolya Rajky

  • ESMO-Magnitude of Clinical Benefit Scale version 1.1

    N.I. Cherny;U. Dafni;J. Bogaerts;N.J. Latino

  • D-Dimer and Prothrombin Fragment 1 + 2 Predict Venous Thromboembolism in Patients With Cancer: Results From the Vienna Cancer and Thrombosis Study

    Cihan Ay;Rainer Vormittag;Daniela Dunkler;Ralph Simanek

  • Bevacizumab, Capecitabine, and Oxaliplatin As Neoadjuvant Therapy for Patients With Potentially Curable Metastatic Colorectal Cancer

    Brigit Gruenberger;Dietmar Tamandl;Johannes Schueller;Werner Scheithauer

  • Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.

    Martin Reck;Alexander Luft;Aleksandra Szczesna;Libor Havel

  • High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS)

    Cihan Ay;Ralph Simanek;Rainer Vormittag;Daniela Dunkler

  • Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trial.

    Thomas Brodowicz;Maciej Krzakowski;Matjaz Zwitter;Valentina Tzekova

  • Oral mucositis complicating chemotherapy and/or radiotherapy: options for prevention and treatment.

    Wolfgang J. Köstler;Michael Hejna;Catharina Wenzel;Christoph C. Zielinski

  • High D-dimer levels are associated with poor prognosis in cancer patients

    Cihan Ay;Daniela Dunkler;Robert Pirker;Johannes Thaler

  • Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

    F. André;C. C. Zielinski

  • Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.

    Giorgio V. Scagliotti;Thomas Brodowicz;Frances A. Shepherd;Christoph Zielinski

Frequent Co-Authors

Matthias Preusser
Matthias Preusser Medical University of Vienna
Michael Gnant
Michael Gnant Medical University of Vienna
Markus Raderer
Markus Raderer Medical University of Vienna
Ingrid Pabinger
Ingrid Pabinger Medical University of Vienna
Erika Jensen-Jarolim
Erika Jensen-Jarolim Medical University of Vienna
Peter Valent
Peter Valent Medical University of Vienna
Raimund Jakesz
Raimund Jakesz Medical University of Vienna
Ursula Wiedermann
Ursula Wiedermann Medical University of Vienna
Otto Scheiner
Otto Scheiner Medical University of Vienna
Werner Scheithauer
Werner Scheithauer Medical University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring careers in medicine doesn’t always mean pursuing a traditional MD. There are a wide range of online degree programs that open doors to dynamic roles within healthcare. These alternative pathways offer flexibility and can be more affordable than traditional routes.

For those interested in healthcare leadership, consider cheap mha programs that prepare graduates for management roles in hospitals, clinics, and public health organizations. Nurses seeking advanced clinical or leadership roles may want to explore the most affordable dnp programs, which allow working professionals to earn a Doctor of Nursing Practice online.

Students drawn to the pharmacy field can look into online pharm d programs that offer the flexibility of distance learning while preparing candidates for careers as pharmacists. Additionally, the field of health information is expanding rapidly; the best online schools for high school students provide early exposure to health information management degrees, connecting students to crucial digital healthcare careers.

These online programs offer flexible scheduling and affordable tuition, making healthcare careers more accessible for students at all stages.

Best Scientists Citing Christoph C. Zielinski

Trending Scientists

Recently Published Articles